Compare Avantis US Small Cap Value ETF (AVUV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Medpace Holdings Inc — how do they compare? Avantis US Small Cap Value ETF trades at $127.5, while Medpace Holdings Inc trades at $601.1 (market cap $16.90B). Which is the better fit depends on your goals.
| AVUV | MEDP | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $128.74 | $620.59 |
52-Week Low | $93.93 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $127.50, up 0.39% with a bullish technical outlook supported by moving averages. The small-cap value ETF is benefiting from strong sector performance, with the Russell 2000 up approximately 20% year-to-date according to 24/7 Wall Street (July 17, 2026). Recent dividend activity includes a $0.44 distribution scheduled for June 2026.
The outlook remains positive as small-cap value continues outperforming growth stocks, with AVUV capturing this premium. Key risks include interest rate sensitivity and regional bank exposure, while institutional sentiment appears favorable given the ETF's role in diversifying tech-heavy portfolios.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
